Literature DB >> 26767119

CRP at early follicular phase of menstrual cycle can cause misinterpretation for cardiovascular risk assessment.

Asli Yarci Gursoy1, Gamze Sinem Caglar1, Mine Kiseli1, Emre Pabuccu1, Tuba Candar2, Selda Demirtas2.   

Abstract

OBJECTIVE: C-reactive protein (CRP) is a well-known marker of inflammation and infection in clinical practice. This study is designed to evaluate CRP levels in different phases of menstrual cycle, which might end up with misleading conclusions especially when used for cardiovascular risk assessment.
METHODS: Twenty-seven women were eligible for the cross-sectional study. Venous blood samples from each participant were collected twice during the menstrual cycle. The first sampling was held at 2nd to 5th days of the menstrual cycle for FSH, estradiol, CRP, and sedimentation, and the second was done at 21st to 24th days of the menstrual cycle for measurement of progesterone, CRP, and sedimentation values.
RESULTS: CRP values were significantly higher in the early follicular phase compared to luteal phase (1.8 mg/L [0.3-7.67] vs. 0.7 mg/L [0.1-8.3], p < 0.001, respectively). In both phases of the menstrual cycle, sedimentation rate was similar (12.1 ± 6.7 vs. 12.3 ± 7.7; p = 0.717, respectively).
CONCLUSIONS: CRP levels in early follicular phase of the menstrual cycle (menstruation) are significantly higher than CRP levels in luteal phase of the same cycle. In reproductive age women, detection of CRP for cardiovascular risk assessment during menstruation might not be appropriate.

Entities:  

Keywords:  CRP; early follicular phase; menstruation

Year:  2015        PMID: 26767119      PMCID: PMC4701164          DOI: 10.1556/1646.7.2015.4.2

Source DB:  PubMed          Journal:  Interv Med Appl Sci        ISSN: 2061-1617


  24 in total

1.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 2.  A unifying biologic explanation for "high-sensitivity" C-reactive protein and "low-grade" inflammation.

Authors:  Irving Kushner; David Samols; Marina Magrey
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

3.  Distribution of C-reactive protein values in the United States.

Authors:  Steven Woloshin; Lisa M Schwartz
Journal:  N Engl J Med       Date:  2005-04-14       Impact factor: 91.245

4.  Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women.

Authors:  Claudine A Blum; Beat Müller; Peter Huber; Marius Kraenzlin; Christian Schindler; Christian De Geyter; Ulrich Keller; Jardena J Puder
Journal:  J Clin Endocrinol Metab       Date:  2005-03-29       Impact factor: 5.958

5.  Effects of synthetic progestagens on autonomic tone, neurohormones and C-reactive protein levels in young healthy females in reproductive age.

Authors:  Per Otto Schueller; Martin Feuring; Yulia Sharkova; Wolfram Grimm; Michael Christ
Journal:  Int J Cardiol       Date:  2005-08-03       Impact factor: 4.164

Review 6.  [High sensitivity C protein as an independent risk factor in people with and without history of cardiovascular disease].

Authors:  Viviana Brito; Andrea Alcaraz; Federico Augustovski; Andrés Pichón-Riviere; Sebastián García-Martí; Ariel Bardach; Agustín Ciapponi; Analía Lopez; Daniel Comandé
Journal:  Arch Cardiol Mex       Date:  2015-02-18

7.  The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration.

Authors:  M H Wener; P R Daum; G M McQuillan
Journal:  J Rheumatol       Date:  2000-10       Impact factor: 4.666

8.  Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy.

Authors:  Brian L Stauffer; Greta L Hoetzer; Derek T Smith; Christopher A DeSouza
Journal:  J Appl Physiol (1985)       Date:  2003-08-29

9.  C-reactive protein across the menstrual cycle.

Authors:  Katherine Wander; Eleanor Brindle; Kathleen A O'Connor
Journal:  Am J Phys Anthropol       Date:  2008-06       Impact factor: 2.868

Review 10.  C-reactive protein and coronary heart disease: a critical review.

Authors:  J P Casas; T Shah; A D Hingorani; J Danesh; M B Pepys
Journal:  J Intern Med       Date:  2008-10       Impact factor: 8.989

View more
  3 in total

1.  Sleep Duration Trajectories and Systemic Inflammation in Young Adults: Results From the National Longitudinal Study of Adolescent to Adult Health (Add Health).

Authors:  Chighaf Bakour; Skai Schwartz; Kathleen O'Rourke; Wei Wang; William Sappenfield; Marisa Couluris; Henian Chen
Journal:  Sleep       Date:  2017-11-01       Impact factor: 5.849

2.  Homocysteine and C-reactive Protein Levels in Women with Polycystic Ovary Syndrome.

Authors:  Murat Gözüküçük; Aslı Yarcı Gürsoy; Emre Destegül; Salih Taşkın; Hakan Şatıroğlu
Journal:  Gynecol Minim Invasive Ther       Date:  2021-11-05

Review 3.  The effects of exercise on vascular markers and C-reactive protein among obese children and adolescents: An evidence-based review.

Authors:  Norizam Salamt; Musilawati Muhajir; Amilia Aminuddin; Azizah Ugusman
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.